These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 752118)

  • 21. [Neoadjuvant chemotherapy, with mitoxantrone, cyclophosphamide and fluorouracil, in operable breast cancer of intermediate stage: first results of a phase II study in 40 patients].
    Lemaire M; Focan C; Desaive C; Closon-Dejardin MT; Duvivier J; Friedman V; Baugnet-Mahieu L; Paridaens R
    Bull Cancer; 1992; 79(9):883-91. PubMed ID: 1486224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma.
    Bellon JR; Shulman LN; Come SE; Li X; Gelman RS; Silver BJ; Harris JR; Recht A
    Cancer; 2004 Apr; 100(7):1358-64. PubMed ID: 15042668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
    Buchholz TA; Garg AK; Chakravarti N; Aggarwal BB; Esteva FJ; Kuerer HM; Singletary SE; Hortobagyi GN; Pusztai L; Cristofanilli M; Sahin AA
    Clin Cancer Res; 2005 Dec; 11(23):8398-402. PubMed ID: 16322301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP.
    Schneider J; Lucas R; Sánchez J; Ruibal A; Tejerina A; Martín M
    Anticancer Res; 2000; 20(6B):4373-7. PubMed ID: 11205274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of refractory metastatic breast cancer with 5-fluorouracil and levofolinic acid as 48 hours continuous venous infusion.
    Gebbia V; Mauceri G; Testa A; Tirrito M; Varvara F; Cucchiara A; Borsellino N; Girlando A; Ferrara M; Caruso F
    Anticancer Res; 1999; 19(3B):2289-92. PubMed ID: 10472346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of repeated delayed hypersensitivity skin tests on skin-test responses.
    Christou NV; Pietsch JB; Meakins JL
    Can J Surg; 1983 Mar; 26(2):139-42. PubMed ID: 6825002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
    Crump M; Tu D; Shepherd L; Levine M; Bramwell V; Pritchard K
    J Clin Oncol; 2003 Aug; 21(16):3066-71. PubMed ID: 12915595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new six-drug antiblastic regimen (R 14) at low doses (micropolychemotherapy) compared to CMF in the treatment of metastatic breast cancer: phase III study.
    Pannuti F; Iafelice G; Martoni A; Fruet F; Angelelli B; Casadei M
    Chemioterapia; 1984 Aug; 3(4):216-9. PubMed ID: 6398121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer.
    Schrohl AS; Meijer-van Gelder ME; Holten-Andersen MN; Christensen IJ; Look MP; Mouridsen HT; Brünner N; Foekens JA
    Clin Cancer Res; 2006 Dec; 12(23):7054-8. PubMed ID: 17114213
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
    Weiss RB; Woolf SH; Demakos E; Holland JF; Berry DA; Falkson G; Cirrincione CT; Robbins A; Bothun S; Henderson IC; Norton L;
    J Clin Oncol; 2003 May; 21(9):1825-35. PubMed ID: 12721260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No difference in delayed hypersensitivity between breast and cervical carcinomas.
    Munzarová M; Kovarík J; Ptácková B; Hlávková J; Kolcová V; Nebeský T
    Neoplasma; 1984; 31(1):95-8. PubMed ID: 6700799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
    Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
    Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delayed hypersensitivity to 5-fluorouracil following topical chemotherapy of cutaneous cancers.
    Mansell PW; Litwin MS; Ichinose H; Krementz ET
    Cancer Res; 1975 May; 35(5):1288-94. PubMed ID: 1120313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integration of full-dose adjuvant chemotherapy with definitive radiotherapy for primary breast cancer: four-year update.
    Glick JH; Fowble BL; Haller DG; Rosato EF; Mackie JA; Weiler C; Glover DJ; Fox KR; Hurwitz S; Goodman RL
    NCI Monogr; 1988; (6):297-301. PubMed ID: 3352774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.
    Kuerer HM; Newman LA; Buzdar AU; Dhingra K; Hunt KK; Buchholz TA; Binkley SM; Strom EA; Ames FC; Ross MI; Feig BW; McNeese MD; Hortobagyi GN; Singletary SE
    Cancer J Sci Am; 1998; 4(4):230-6. PubMed ID: 9689981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of cyclophosphamide on immunological responses in patients with breast cancer relating to BRM (biological response modifiers)].
    Kimura M; Kanazawa K; Koida T
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):549-53. PubMed ID: 3873910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
    Knoop AS; Knudsen H; Balslev E; Rasmussen BB; Overgaard J; Nielsen KV; Schonau A; Gunnarsdóttir K; Olsen KE; Mouridsen H; Ejlertsen B;
    J Clin Oncol; 2005 Oct; 23(30):7483-90. PubMed ID: 16234514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paclitaxel and 5-fluorouracil in metastatic breast cancer: the US experience.
    Paul DM; Garrett AM; Meshad M; DeVore RD; Porter LL; Johnson DH
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):48-52. PubMed ID: 8629038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delayed cutaneous hypersensitivity and human renal allotransplantation.
    Rolley RT; Sterioff S; Parks LC; Williams GM
    Transplant Proc; 1977 Mar; 9(1):81-3. PubMed ID: 325815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.